Paratek eyes FDA filing as acne drug clears late-stage trials

Boston-based Paratek Pharmaceuticals and Irish drugmaker Allergan said Monday that their acne treatment sarecycline had succeeded in a pair of Phase 3 studies, boosting shares of both companies and setting the stage for an FDA filing later this year. Paratek (Nasdaq: PRTK) and Allergan (NYSE:AGN) said that the drug, a once-daily antibiotic, had easily outperformed a placebo in treating inflammatory lesions in patients with moderate to severe acne after 12 weeks. Based on the data, Allergan now plans…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news